Form 4: GALT CFO Exercises, Sells $470K in Stock

Galectin Therapeutics CFO Jack W. Callicutt executed pre-planned transactions, exercising options and selling 77,920 shares for over $470,000.

Summary

• Galectin Therapeutics Inc. CFO Jack W. Callicutt engaged in multiple transactions involving the exercise of stock options and subsequent sale of common stock on November 17 and 18, 2025.
• All transactions were conducted under a Rule 10b5-1 plan established on April 17, 2025, and previously disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• On November 17, 2025, Callicutt exercised options for 9,586 shares at $1.98, 19,701 shares at $1.11, and 2,323 shares at $1.23. These 31,610 shares were then sold at a weighted average price of $6.0317.
• On November 18, 2025, Callicutt exercised options for 28,100 shares at $1.98 and 18,210 shares at $1.11. These 46,310 shares were then sold at a weighted average price of $6.223.
• In total, 77,920 shares were acquired through option exercises and subsequently sold.
• Following these transactions, Callicutt directly beneficially owns 7,614 shares of common stock.
• Remaining derivative securities include 28,120 stock options exercisable at $1.98 (expiring 01/24/2032), 18,190 at $1.11 (expiring 01/26/2034), and 48,750 at $1.23 (expiring 01/22/2035).

Sentiment

Score: 4

Explanation: While the transactions were pre-planned under a 10b5-1 plan, the significant reduction in the CFO's direct common stock ownership could be perceived as a slight negative by some investors, even if the sales were for personal financial planning. The high profit margin for the insider is a positive for the individual, but not directly for the company's stock outlook.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating the sales were scheduled in advance and not based on new, material non-public information.
• The CFO realized significant gains, with sale prices ranging from $6.00 to $6.30, substantially higher than the exercise prices of $1.11, $1.23, and $1.98, resulting in an estimated profit of approximately $359,355.65.

Negatives

• The CFO sold a substantial number of shares (77,920), reducing direct beneficial ownership of common stock to 7,614 shares.
• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• **Shareholders**: The sale of a significant number of shares by a key executive, even if pre-planned, might be interpreted by some shareholders as a signal, potentially leading to minor negative sentiment. However, the 10b5-1 plan mitigates concerns about opportunistic selling.
• **Employees**: No direct impact on employees is indicated by this filing.
• **Customers/Suppliers/Creditors**: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

The filing details pre-planned insider selling by the CFO, which, while reducing direct equity ownership, was executed under a Rule 10b5-1 plan. This mitigates concerns about opportunistic selling based on non-public information. The transactions reflect the CFO monetizing vested options at favorable prices, which is a personal financial event rather than a direct indicator of the company's future performance. Without additional company-specific news or broader market context, this Form 4 alone does not warrant a change from a 'hold' position, as it represents expected, routine insider activity.

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Trading, Stock Options, CFO, Jack W. Callicutt, Equity Sales, Rule 10b5-1 Plan, Beneficial Ownership